TY - JOUR
T1 - HIV incidence among injecting drug users in New York City syringe-exchange programmes
AU - Des Jarlais, Don C.
AU - Marmor, Michael
AU - Paone, Denise
AU - Titus, Stephen
AU - Shi, Qiuhu
AU - Perlis, Theresa
AU - Jose, Benny
AU - Friedman, Samuel R.
N1 - Funding Information:
Our research was supported by American Foundation for AIDS Research Syringe Exchange Evaluation grant, National Institute on Drug Abuse (grants DA03574, DA06001, DA05283, and DA06723), and by the HIV Vaccine Efficacy Trials Network of the National Institute of Allergy and Infectious Diseases (NIAID) via Abt Associates Inc (subcontract SUB-JMEISTER-NYU-12/8/94, under NIAID prime contract NO1-A1-35176). We thank Judith Milliken, Thomas P Ward, and Jessica Clark for editorial assistance and expertise during the preparation of this manuscript.
PY - 1996/10/12
Y1 - 1996/10/12
N2 - Background. There have been no studies showing that participation in programmes which provide legal access to drug-injection equipment leads to individual-level protection against incident HIV infection. We have compared HIV incidence among injecting drug users participating in syringe-exchange programmes in New York City with that among non-participants. Methods. We used meta-analytic techniques to combine HIV incidence data from injecting drug users in three studies: the Syringe Exchange Evaluation (n = 280), in which multiple interviews and saliva samples were collected from participants at exchange sites; the Vaccine Preparedness Initiative cohort (n = 133 continuing exchangers and 188 non-exchangers, in which participants were interviewed and tested for HIV every 3 months; and very-high-seroprevalence cities in the National AIDS Demonstration Research (NADR) programme (n = 1029), in which street-recruited individuals were interviewed and tested for HIV every 6 months. In practice, participants in the NADR study had not used syringe exchanges. Findings. HIV incidence among continuing exchange-users in the Syringe Exchange Evaluation was 1.58 per 100 person-years at risk (95% CI 0.54, 4.65) and among continuing exchange-users in the Vaccine Preparedness Initiative it was 1.38 per 100 person-years at risk (0.23, 4.57). Incidence among non-users of the exchange in the Vaccine Preparedness Initiative was 5.26 per 100 person-years at risk (2.41, 11.49), and in the NADR cities, 6.23 per 100 person-years at risk (4.4, 8.6). In a pooled-data, multivariate proportional-hazards analysis, not using the exchanges was associated with a hazard ratio of 3.35 (95% CI 1.29, 8.65) for incident HIV infection compared with using the exchanges. Interpretation. We observed an individual-level protective effect against HIV infection associated with participation in a syringe-exchange programme. Sterile injection equipment should be legally provided to reduce the risk of HIV infection in persons who inject illicit drugs.
AB - Background. There have been no studies showing that participation in programmes which provide legal access to drug-injection equipment leads to individual-level protection against incident HIV infection. We have compared HIV incidence among injecting drug users participating in syringe-exchange programmes in New York City with that among non-participants. Methods. We used meta-analytic techniques to combine HIV incidence data from injecting drug users in three studies: the Syringe Exchange Evaluation (n = 280), in which multiple interviews and saliva samples were collected from participants at exchange sites; the Vaccine Preparedness Initiative cohort (n = 133 continuing exchangers and 188 non-exchangers, in which participants were interviewed and tested for HIV every 3 months; and very-high-seroprevalence cities in the National AIDS Demonstration Research (NADR) programme (n = 1029), in which street-recruited individuals were interviewed and tested for HIV every 6 months. In practice, participants in the NADR study had not used syringe exchanges. Findings. HIV incidence among continuing exchange-users in the Syringe Exchange Evaluation was 1.58 per 100 person-years at risk (95% CI 0.54, 4.65) and among continuing exchange-users in the Vaccine Preparedness Initiative it was 1.38 per 100 person-years at risk (0.23, 4.57). Incidence among non-users of the exchange in the Vaccine Preparedness Initiative was 5.26 per 100 person-years at risk (2.41, 11.49), and in the NADR cities, 6.23 per 100 person-years at risk (4.4, 8.6). In a pooled-data, multivariate proportional-hazards analysis, not using the exchanges was associated with a hazard ratio of 3.35 (95% CI 1.29, 8.65) for incident HIV infection compared with using the exchanges. Interpretation. We observed an individual-level protective effect against HIV infection associated with participation in a syringe-exchange programme. Sterile injection equipment should be legally provided to reduce the risk of HIV infection in persons who inject illicit drugs.
UR - http://www.scopus.com/inward/record.url?scp=0242409954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242409954&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(96)02536-6
DO - 10.1016/S0140-6736(96)02536-6
M3 - Article
C2 - 8855855
AN - SCOPUS:0242409954
SN - 0140-6736
VL - 348
SP - 987
EP - 991
JO - Lancet
JF - Lancet
IS - 9033
ER -